Literature DB >> 19318346

Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis.

C Goubau1, M Wilschanski, V Skalická, P Lebecque, K W Southern, I Sermet, A Munck, N Derichs, P G Middleton, L Hjelte, R Padoan, M Vasar, K De Boeck.   

Abstract

BACKGROUND: In patients with symptoms suggestive of cystic fibrosis (CF) and intermediate sweat chloride values (30-60 mmol/l), extensive CFTR gene mutation analysis and nasal potential difference (NPD) measurement are used as additional diagnostic tests and a positive result in either test provides evidence of CFTR dysfunction. To define the phenotype of such patients and confirm the validity of grouping them, patients with intermediate sweat chloride values in whom either additional CF diagnostic test was abnormal were compared with subjects in whom this was not the case and patients with classic CF.
METHODS: The phenotypic features of four groups were compared: 59 patients with CFTR dysfunction, 46 with an intermediate sweat chloride concentration but no evidence of CFTR dysfunction (CF unlikely), 103 patients with CF and pancreatic sufficiency (CF-PS) and 62 with CF and pancreatic insufficiency (CF-PI).
RESULTS: The CFTR dysfunction group had more lower respiratory tract infections (p = 0.01), more isolation of CF pathogens (p<0.001) and clubbing (p = 0.001) than the CF unlikely group, but less frequent respiratory tract infections with CF pathogens than the CF-PS group (p = 0.05). Patients in the CF-PS group had a milder phenotype than those with PI. Many features showed stepwise changes through the patient groups.
CONCLUSION: Patients with intermediate sweat chloride values and two CFTR mutations or an abnormal NPD measurement have a CF-like phenotype compatible with CFTR dysfunction and, as a group, differ phenotypically from patients with intermediate sweat chloride values in whom further CF diagnostic tests are normal as well as from CF-PS and CF-PI patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318346     DOI: 10.1136/thx.2008.104752

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Cystic fibrosis papers of the year 2009.

Authors:  Ian M Balfour-Lynn
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

2.  Screening for the Most Common Mutations of CFTR Gene among Egyptian Children with Difficult-to-Treat Asthma.

Authors:  Mohammad Al-Haggar; Engy Osman; Abdel-Rahman Eid; Tarek Barakat; Samar El-Morsi
Journal:  J Pediatr Genet       Date:  2020-02-03

3.  An international randomized multicenter comparison of nasal potential difference techniques.

Authors:  George M Solomon; Michael W Konstan; Michael Wilschanski; Joanne Billings; Isabelle Sermet-Gaudelus; Frank Accurso; François Vermeulen; Elina Levin; Heather Hathorne; Ginger Reeves; Gina Sabbatini; Aubrey Hill; Nicole Mayer-Hamblett; Melissa Ashlock; John Paul Clancy; Steven M Rowe
Journal:  Chest       Date:  2010-05-14       Impact factor: 9.410

4.  Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.

Authors:  Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

5.  Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.

Authors:  Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Valeria Thompson; Bonnie W Ramsey; Wayne Morgan; Ronald L Gibson
Journal:  J Cyst Fibros       Date:  2012-05-01       Impact factor: 5.482

6.  Assessment of Correlation between Sweat Chloride Levels and Clinical Features of Cystic Fibrosis Patients.

Authors:  Manzoor A Raina; Mosin S Khan; Showkat A Malik; Ab Hameed Raina; Mudassir J Makhdoomi; Javed I Bhat; Syed Mudassar
Journal:  J Clin Diagn Res       Date:  2016-12-01

7.  What can the CF registry tell us about rare CFTR-mutations? A Belgian study.

Authors:  E De Wachter; M Thomas; S S Wanyama; S Seneca; A Malfroot
Journal:  Orphanet J Rare Dis       Date:  2017-08-22       Impact factor: 4.123

8.  Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice.

Authors:  Emilie Lyne Saussereau; Delphine Roussel; Siradiou Diallo; Laurent Debarbieux; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

9.  Unsolved severe chronic rhinosinusitis elucidated by extensive CFTR genotyping.

Authors:  Fanny Degrugillier; Stéphanie Simon; Abdel Aissat; Natascha Remus; Chadia Mekki; Xavier Decrouy; Aurélie Hatton; Alexandre Hinzpeter; Brice Hoffmann; Isabelle Sermet-Gaudelus; Isabelle Callebaut; Pascale Fanen; Virginie Prulière-Escabasse
Journal:  Clin Case Rep       Date:  2019-09-27

10.  Clinical and molecular characterization of the R751L-CFTR mutation.

Authors:  Iram J Haq; Mike Althaus; Aaron Ions Gardner; Hui Ying Yeoh; Urjita Joshi; Vinciane Saint-Criq; Bernard Verdon; Jennifer Townshend; Christopher O'Brien; Mahfud Ben-Hamida; Matthew Thomas; Stephen Bourke; Peter van der Sluijs; Ineke Braakman; Chris Ward; Michael A Gray; Malcolm Brodlie
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-12-09       Impact factor: 5.464

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.